Field Application Scientist, Cell Signaling TechnologyBiography
Jonah Riddell received bachelors in chemistry and physics from Saint Bonaventure University in New York. Continued education included a master's degree in oncology from Roswell Park Cancer Institutes' department of biophysics/biochemistry where he was the first to crystalize the ologomeric form of Peroxiredoxin 1. During Ph.D. work in the RPCI division of the State University of NY at Buffalo program in immunology and cancer immunity he identified and characterized a novel prostate cancer antigen, now in clinical trials, that was found to play multiple roles in promoting prostate cancer. Post-doctoral completed at the Harvard Stem Cell Institute/Boston Children's Hospital succeeded in reprogramming murine differentiated blood cells into hematopoietic stem cells in work that hopefully can be pushed to the clinic and help patients undergoing bone marrow transplants. Peer reviewed research articles and two patents have shown his investment in clinically oriented therapies toward cancer. He continues his goals of aiding researchers by providing reliable and quality products from Cell Signaling Technology to researchers and clinicians so that millions of researchers can bear the torches to illuminate numerous novel disease therapies.